CTChristopher J. Tichacek

Christopher J. Tichacek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher J. Tichacek has a total of 18 co-authors. Here are the top co-authors by number of shared publications:

  • David L. Morse

    Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

    2 shared publications
  • HyunJoo Kil

    Department of Pharmaceutical Sciences, West Virginia University, Health Sciences Center, Morgantown, West Virginia 26506, United States

    2 shared publications
  • Kenneth L. Gage

    Radiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

    2 shared publications
  • Mark L. McLaughlin

    Department of Pharmaceutical Sciences, West Virginia University, Health Sciences Center, Morgantown, West Virginia 26506, United States

    2 shared publications
  • Michael Doligalski

    Department of Cancer Physiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

    2 shared publications
  • Mikalai M. Budzevich

    Small Animal Imaging Laboratory, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida 33612, United States

    2 shared publications

Latest Publications

  • Lipophilicity Determines Routes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting Peptide Receptor Radiotherapy

    by Narges K. Tafreshi, HyunJoo Kil, Darpan N. Pandya, Christopher J. Tichacek, Michael L. Doligalski, Mikalai M. Budzevich, Nella C. Delva, Michael L. Langsen, John A. Vallas, David C. Boulware, et al.

    Lipophilicity is explored in the biodistribution (BD), pharmacokinetics (PK), radiation dosimetry (RD), and toxicity of an internally administered targeted alpha-particle therapy (TAT) under development for the treatment of metastatic melanoma. The TAT conjugate is comprised of the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetate), conjugated to melanocortin receptor 1 specific peptidic ligand (MC1RL) using a linker moiety and chelation of the 225Ac radiometal. A set of conjugates were prepared with a range of lipophilicities (log D7.4 values) by varying the chemical properties of the linker. Reported are the observations that higher log D7.4 values are associated with decreased kidney uptake, decreased absorbed radiation dose, and decreased kidney toxicity of the TAT, and the inverse is observed for lower log D7.4 values. Animals administered TATs with lower lipophilicities exhibited acute nephropathy and death, whereas animals administered the highest activity TATs with higher lipophilicities lived for the duration of the 7 month study and exhibited chronic progressive nephropathy. Changes in TAT lipophilicity were not associated with changes in liver uptake, dose, or toxicity. Significant observations include that lipophilicity correlates with kidney BD, the kidney-to-liver BD ratio, and weight loss and that blood urea nitrogen (BUN) levels correlated with kidney uptake. Furthermore, BUN was identified as having higher sensitivity and specificity of detection of kidney pathology, and the liver enzyme alkaline phosphatase (ALKP) had high sensitivity and specificity for detection of liver damage associated with the TAT. These findings suggest that tuning radiopharmaceutical lipophilicity can effectively modulate the level of kidney uptake to reduce morbidity and improve both safety and efficacy.


  • Biodistribution and Multicompartment Pharmacokinetic Analysis of a Targeted α Particle Therapy

    by Christopher J. Tichacek, Narges K. Tafreshi, HyunJoo Kil, Robert W. Engelman, Michael L. Doligalski, Mikalai M. Budzevich, Kenneth L. Gage, Mark L. McLaughlin, Thaddeus J. Wadas, Ariosto Silva, et al.

    Targeted alpha particle therapy (TAT) is ideal for treating disease while minimizing damage to surrounding non-targeted tissues due to short path-length and high linear energy transfer (LET). We developed a TAT for metastatic uveal melanoma, targeting the melanocortin 1 receptor (MC1R), which is expressed in 94% of uveal melanomas. Two versions of the therapy are being investigated: 225Ac-DOTA-Ahx-MC1RL (225Ac-Ahx) and 225Ac-DOTA-di-D-Glu-MC1RL (225Ac-di-D-Glu). The biodistribution (BD) from each was studied and a multi-compartment pharmacokinetic (PK) model was developed to describe drug distribution rates. Two groups of 16 SCID mice bearing high MC1R expressing tumors were intravenously injected with 225Ac-Ahx or 225Ac-di-D-Glu. After injection, 4 groups (n=4) were euthanized at 24, 96, 144, and 288 hour time-points for each cohort. Tumors and 13 other organs were harvested at each time point. Isomeric gamma spectra were measured in tissue samples using a scintillation gamma detector and converted to alpha activity using factors for gamma ray abundance per alpha decay. Time activity curves were calculated for each organ. A 5-compartment PK model was built with the following compartments: blood, tumor, normal tissue, kidney, and liver. This model is characterized by a system of 5 ordinary differential equations using mass action kinetics which describe uptake, inter-compartmental transitions and clearance rates. The ordinary differential equations were simultaneously solved and fit to experimental data using a genetic algorithm for optimization. The BD data show that both compounds have minimal distribution to organs at risk other than kidney and liver. The PK parameter estimates had less than 5% error. From these data, the 225Ac-Ahx showed larger and faster uptake in the liver. Both compounds had comparable uptake and clearance rates for other compartments. The BD and PK behavior for two targeted radiopharmaceuticals were investigated. The PK model fit the experimental data and provided insight into the kinetics of the compounds systematically.